LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Current Assets
All assets expected to be converted to cash or used up within one year.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 2532.3% from a year ago
Total current assets stood at $389.07M at the end of Q1 FY2026, up 2532.3% from a year earlier and up 26.1% from the prior quarter. Over 3 fiscal years it compounded at +143.0% a year.
Context
- Total current assets amounted to 98.9% of total assets at the end of Q1 FY2026, up 22.1 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +2532.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 308.43M USD
- Year-over-year change
- +968.0%
- 3-year CAGR
- +143.0%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 308.43M | +968.0% |
| FY2024 | 2024-12-31 | 28.88M | -36.7% |
| FY2023 | 2023-12-31 | 45.63M | +112.4% |
| FY2022 | 2022-12-31 | 21.49M | — |
Total Current Assets vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total current assets of $389.07M is the 6th highest of the 10 companies compared; the peer median is $484.7M.
- Its year-over-year change of +2532.3% is the 2nd highest of 10, against a peer median of +64.6%.
- Total current assets amounts to 98.9% of total assets for LBRX, versus a peer median of 97.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $79.73B | +512730.9% | +27.4% | 83.9% | |
| Sep 2026 | $1.27B | +17.8% | +27.9% | 70.7% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $1.05B | +387.3% | +42.1% | 97.9% |
| Jun 2026 | $753.93M | -19.3% | -13.1% | 65.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $484.7M | +66.6% | +151.7% | 97.4% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $389.07M | +2532.3% | +143.0% | 98.9% |
| Mar 2026 | $327.23M | +233.0% | +116.4% | 78.1% | |
| Mar 2026 | $272.23M | -7.6% | +19.3% | 98.9% | |
| Mar 2026 | $269.13M | +64.6% | +53.4% | 97.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.43M | -39.8% | -21.1% | 99.7% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $484.7M | +64.6% | +27.9% | 97.4% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.